When was LambdaVision founded?

LambdaVision was founded in 2009.

Where is LambdaVision located?

LambdaVision is located in Farmington, United States .

Who is the current CEO of LambdaVision?

Nicole Wagner is the current CEO of LambdaVision.

How many employees does LambdaVision have?

LambdaVision has 7 employees as of Dec 31, 2021.

Is LambdaVision a funded company?

LambdaVision is a funded company, its first funding round was on Oct 03, 2011.

When was the latest funding round of LambdaVision?

LambdaVision's latest funding round was on May 29, 2024.

Where does LambdaVision rank among its competitors?

LambdaVision ranks 26 amongst 144 active competitors.

Who are the top competitors of LambdaVision?

LambdaVision's top competitors are 4D Molecular Therapeutics, EyePoint Pharmaceuticals and Rezolute.

LambdaVision - 2025 Company Profile, Funding & Competitors

Company Details

Provider of a protein-based retinal prosthesis for retinal degenerative diseases. The company harnesses the photochemical properties of retinylidene proteins to develop a high-resolution, protein-based retinal prosthesis for the restoration of vision and improvement of the quality of life for those patients afflicted by retinal degenerative diseases, including age-related macular degeneration and retinitis pigmentosa.

Website
Social

Key Metrics

Founded Year

2009

Location

Farmington, United States

Stage

Series A

Total Funding

in 9 rounds

Latest Funding Round

Investors

Aurelia Foundry & 8 more

Ranked

26^th among

Employee Count

as on Dec 31, 2021

Similar Companies

4D Molecular Therapeutics &

Legal entities associated with LambdaVision

LambdaVision is associated with 1 legal entity given below:

Legal Entity Name	Date of incorporation	Revenue	Net Profit	Employee Count
	Dec 31, 2008	-	651	573

Get your free copy of LambdaVision's company profile

LambdaVision has raised a total funding of $650K over 9 rounds. Its first funding round was on Oct 03, 2011. Its latest funding round was a Series A round on May 29, 2024 for an undisclosed amount. 3 investors participated in its latest round, which includes , E2MC, Connecticut Innovations and Design Technologies.

LambdaVision has 9 institutional investors including Aurelia Foundry, and E2MC.

Here is the list of recent funding rounds of LambdaVision:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
May 29, 2024	Undisclosed	Series A	3468796	9557086	, E2MC, and
Sep 04, 2020	Undisclosed	Grant (prize money)	8554800	2210614
Oct 16, 2017	$500K	Series A	6030728	9719274	Connecticut Innovations

Access funding benchmarks and valuations. Sign up today!

View details of LambdaVision's funding rounds and investors

LambdaVision's employee count trend

LambdaVision has 7 employees as of Dec 21. The total employee count is 16.7% more than what it was in Dec 20. Here is LambdaVision's employee count trend over the years:

Uncover LambdaVision's growth story! Sign up today!

Top competitors of LambdaVision include 4D Molecular Therapeutics, EyePoint Pharmaceuticals and Rezolute. Here is the list of Top 10 competitors of LambdaVision, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Longevity Vision Fund, Janus Henderson Investors听&补尘辫;听	66/100
2nd	EyePoint Pharmaceuticals 1987, Watertown (United States), Public	Developer of small molecule-based therapeutics for treating ophthalmic disorders	-	Rosalind Advisors, OcuMension听&补尘辫;听	65/100
3rd	Rezolute 2012, Denver (United States), Public	Biopharmaceutical company developing therapies for metabolic & orphan diseases	-	Collage Venture Partners, Citadel听&补尘辫;听	61/100
4th	Molecular Partners 2004, Zurich (Switzerland), Public	Developer of therapeutic solutions for treating multiple diseases	$59.9M	Johnson & Johnson Innovation 鈥� JJDC, BB Biotech Ventures听&补尘辫;听	58/100
5th	Aviceda Therapeutics 2018, Cambridge (United States), Series C	Developer of biotherapeutics for glycol-immune diseases	$255M	Orbimed, TCG Crossover听&补尘辫;听	58/100
6th	RevBio 2014, Lowell (United States), Series A	Developer of synthetic adhesive used for bone/dental repair	$24.4M	MassChallenge, University of Pittsburgh听&补尘辫;听	56/100
7th	Epicrispr Bio 2018, San Francisco (United States), Series B	Developer of therapeutics for multiple disease	$68M	LDV Partners, Ally Bridge Group听&补尘辫;听	55/100
8th	Relmada 2007, Blue Bell (United States), Public	Developing novel drug products for the treatment of multiple disease	$13M	Olympus Capital Investments, Ben Franklin Technology Partners听&补尘辫;听	55/100
9th	CureVac 2000, Tubingen (Germany), Public	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	GSK, 听&补尘辫;听	54/100
10th	Sydnexis 2014, Del Mar (United States), Series B	Developer of a therapeutic formulation for treating myopia	$71.5M	Longitude Capital, RA Capital Management听&补尘辫;听	54/100
26th	LambdaVision 2009, Farmington (United States), Series A	Provider of a protein-based retinal prosthesis for retinal degenerative diseases	$650K	, E2MC听&补尘辫;听	47/100